Interferone pp 420-436 | Cite as

Therapiemodalitäten

  • E. Bonnem
  • P. von Wussow

Zusammenfassung

Bis vor ca. 10 Jahren standen dem Arzt zur Behandlung von Tumoren nur Chirurgie, Bestrahlung und Chemotherapie zur Verfügung. Als vierte Option etabliert sich mehr und mehr die „Immuntherapie“, die gegenwärtig zum großen Teil auf der Anwendung von Biologischen Response Modifiern beruht. Die IFNe-α stellen die als erste „Biological Response Modifiers“ dar, die klinisch ausgetestet wurden. Für viele Tumorindikationen ist der Stellenwert der IFN-Monotherapie bereits erarbeitet und etabliert (s. Kapitel „Die Monotherapie mit Interferonen bei soliden Tumoren und hämatologischen Erkrankungen“). Hingegen hat die klinische Austestung von IFN und Zytostatikakombinationen erst begonnen. Wichtig und notwendig bei der Entwicklung von IFN-Zytostatika-Kombinationen sind Erkenntnisse über die Wirkungsweise von IFNen, Zytostatika und deren Kombinationen, die bis heute jedoch erst sehr rudimentär vorliegen. Besonders problematisch für die Erarbeitung einer neuen IFN-Zytostatika-Kombination ist die Unkenntnis darüber, welcher der zahlreichen bekannten in vitro Wirkungsmechanismen für die in vivo beobachtete antitumorale Aktivität der IFNe verantwortlich ist. Denn IFNe wirken sowohl direkt auf Tumorzellen, in dem sie das Wachstum hemmen, Zellmembranen verändern und intrazelluläre Proteine in den Tumorzellen induzieren [1]. IFNe wirken aber auch auf den Gesamtorganismus, in dem sie verschiedene Immuneffektorzellen wie Monozyten oder Lymphozyten aktivieren. Durch diese Aktivierung können die IFNe auch indirekt antitumoral wirken [2]. Eine Reihe von hypothetischen Mechanismen könnte eine Kombination von IFN und Zytostatika sinnvoll erscheinen lassen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Tamm I, Jasny BR, Pfeffer LM (1987) Antiproliferative action of interferons. In: Mechanism of IFN-action, LM Pfeffer CRC Press, Inc. Florida, Vol. IGoogle Scholar
  2. 2.
    Johnson, HM (1987) Interferon-mediated modulation of the human System. In: Mechanism of IFN-action, LM Pfeffer CRC Press, Inc. Florida, Vol. IGoogle Scholar
  3. 3.
    Balkwill FR, Mowskowitz S, Seilmann SS, Moodie EM, Griffen DB, Fantes KH, Wolf CR (1984) Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drugmetabolizing enzymes. Cancer Res 44: 5249–5255PubMedGoogle Scholar
  4. 4.
    Clark RH, Dimitrov NV, Axelson JA et al (1983) Leukocyte interferon as a biological modifier in lymphoproliferative diseases resistant to standard therapy. Blood 62: 188a (suppl)Google Scholar
  5. 5.
    Clark RH, Dimitrov NV, Axelson JA, et al (1984) Leukocyte interferon as a possible biological response modifier in lymphoproliferative disorders resistant to standard the-rapy. J Biol Resp Mod 3: 613–619Google Scholar
  6. 6.
    Lister TA (personal communication)Google Scholar
  7. 7.
    Chisesi T, Capnist G, Vespignani M, et al (1987) Interferon alpha-2b and chlorambucil in the treatment of Non-Hodgkin’s lymphoma. Invest New Drugs 5: 535–540CrossRefGoogle Scholar
  8. 8.
    Aapro MS, Alberts DSD, Salmon SE (1983) Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 10: 161–166PubMedCrossRefGoogle Scholar
  9. 9.
    Namba M, Yamamoto S, Tanaka H, Kanamori T, Nobuhara M, Kimoto T (1984) In vitro and in vivo studies on potentation of cytotoxic effects of anticancer drugs or cobalt 60 gamma ray by interferon on human neoplastic cells. Cancer 54: 2262–2267PubMedCrossRefGoogle Scholar
  10. 10.
    Cooper MR, Fefer A, Thompson J, et al (1986) Alpha-2-interferon/melphalan/prednisone in previously untreated patients with pultiople myeloma: A Phase I–II trial. Cancer Treat Rep 70: 473–476Google Scholar
  11. 11.
    Mellstedt (personal communication) V. Hannover Interferone Workshop (Abstract)Google Scholar
  12. 12.
    Gresser I, Hanry C, Tovey M (1978) Efficancy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice. Eur J Cancer 14: 97–99PubMedCrossRefGoogle Scholar
  13. 13.
    Kangas L, Cantell K, Grönroos M, Mäenpää J, Perilä M: Antitumor effect of interferons, cytostatic drugs and their combinations in subrenal capsule assay (SRCA). Ann Chir Gynaecol 199: 60–63Google Scholar
  14. 14.
    Balkwill FR, Moodie EM (1984) Positive interactions between human interferon and cyclophosphamide or andiamycin in a human tumor model system. Cancer Res 44: 904–908PubMedGoogle Scholar
  15. 15.
    Clouse L, Braich T, Grimm M, et al (1986) A Phase I trial of oral cyclophosphamide and subcutaneous alpha-2b-interferon in patients with malignant disease. Proc Am Soc Clin One 5: 228 (abstr)Google Scholar
  16. 16.
    Ozer H, Anderson JR, Peterson BA, et al (1987) Combination trial of subcutaneous interferon alpha-2b and oral cyclophosphamide in favorable histology Non-Hodgkin’s lymphoma. Invest New Drugs 5: 524–534CrossRefGoogle Scholar
  17. 17.
    Mannering GJ, Renton KW, Elazhary R, Delora L (1980) Effects of IFN-inducing agents on hepatic cytochrome P 450 drug metabolizing systems. Ann NY Acad Sci 350: 314–317PubMedCrossRefGoogle Scholar
  18. 18.
    McLeod GR, Thomas DB, Hersey P (1987) Recombinant interferon alpha-2a in advanced malignant melanoma; A Phase I–II study in combination with DTIC. Int J Cancer (Suppl) 1: 31–35Google Scholar
  19. 19.
    Vorobiof DA, Falkson G, Voges CW (1989) DTIC versus DTIC and recombinant interferon alpha 2b (rIFN-a2b) in the treatment of patients with advanced malignant melanoma. Proc Am Soc Clin One, Vol. 8, 284Google Scholar
  20. 20.
    Bagetta E, Negretti E, Gianotti B, et al: Phase II study of interferon alpha 2a (rlFN- a2a) and dacarbazine (DTIC) in metastatic melanomaGoogle Scholar
  21. 21.
    Kerr R, Pippen P, Meunel R, Jones S: Treatment of metastatic malignant melanoma with a combination of IFN-a-2a and decarbazine. Proc ASCO 89, abstract 1122Google Scholar
  22. 22.
    Welander CE, Morgan TM, Homesley HD, Trotta PP, Spiegel RJ (1985) Combined recombinant human interferon alpha-A2 cytotoxic agents studied in a clonogenic assay. Int J Cancer 35: 721–729PubMedCrossRefGoogle Scholar
  23. 23.
    Welander CE, Muss HB, Homesley HD, et al (1985) Phase II trial of combined human interferon alpha-2 and doxorubicin. Proc Am Soc Clin One 4: 220 (abstr)Google Scholar
  24. 24.
    Welander CE, Muss HB, Homesley HD, et al (1985) Phase II trial of combined human interferon alpha-2 and doxorubicin. Int J Cancer 35: 721–729PubMedCrossRefGoogle Scholar
  25. 25.
    Sarosy GA, Brown TD, von Hoff DD, et al (1986) Phase I study of alpha-2-interferon plus doxorubicin in patients with solid tumors. Cancer Res 46: 5368–5371PubMedGoogle Scholar
  26. 26.
    Suhadolnik RJ, Sawada Y, Flick MB, Reichenbach NL, Mosca JD (1983) Effect of human fibroblast interferon on the antiviral activity of mammalian cells treated with bleomycin, vincristine or mitomycin C1. Cancer Res 43: 5462–5466PubMedGoogle Scholar
  27. 27.
    Figlin RA, deKernion JB, Maldazys J, et al (1984) Human leukocyte interferon/vinblastine therapy for renal cell carcinoma. Proc Am Soc Clin One 3: 49 (abstr)Google Scholar
  28. 28.
    Ravdin P, Tuttle R, Davis TE, Trump DL, et al (1985) Phase I/II trial of human lymphoblastoid interferon and continuous infusion vinblastine in advanced renal cell cancer. Proc Am Soc Clin One 4: 101 (abstr)Google Scholar
  29. 29.
    Getto GL, Franceschi T, Bassetto MA, et al (1986) Phase I/II trial of recombinant al- pha-2-IFN and vinblastine in metastatic renal cell carcinoma. Proc Am Soc Clin One 5: 110 (abstr)Google Scholar
  30. 30.
    Fossa SD, de Garis ST, Heie MS, Flokkmann A, Lien HH, Salveson A, Moe B (1986) Recombinant interferon alpha-2a with or without vinblastine in metastatic renal cell carcinoma. Cancer 57: 1700–1704PubMedGoogle Scholar
  31. 31.
    Figlin RA, de-Kernion JB; Maldazys J, Sarna B (1985) Treatment of renal cell carcinoma with a (human leukocyte) interferon and vinblastine in combination. A-phase I-II trial. Cancer Treat Rep 69: 263–267Google Scholar
  32. 32.
    Rios A, Mansell P, Newell G, et al (1985) The use of lymphoblastoid interferon and vinblastine in the treatment of acquired immunodeficiency syndrome related Kaposi’s sarcoma. Proc Am Soc Clin One 4: 6 (abstr)Google Scholar
  33. 33.
    Krown SE, Real FX: Preliminary observations in the effects of leukocyte recombinant IFN-A in homosexual men with Kaposi’s sarcoma. New Engl J Med 308: 1071–76Google Scholar
  34. 34.
    Lonberg M, Odajnyk C, Krigel R, et al (1985) Sequential and simultaneous alpha-2- interferon and VP-16 in epidemic Kaposi’s sarcoma. Proc Am Soc Clin One 4: 2 (abstr)Google Scholar
  35. 35.
    Miyoshi T, Ogawa S, Kanamori T, Mobuhara M, Namba M (1983) Interferon potentiates cytotoxic effects of 5-fluorouracil on cell proliferation of established human cell lines originating from neoplastic tissues. Cancer Lett 17: 239–2436.PubMedCrossRefGoogle Scholar
  36. 36.
    Ligo, M, Galzer RI (1985) Antagonistic effect of polycytidylic acid on the cell lethality produced by 5-fluorouracil in human colon carcinoma cells in vitro. Cancer Res 45: 1953–1957Google Scholar
  37. 37.
    Wadler S, Wiernik PH (1988) 5-Fluorouracil and recombinant alpha-2 interferon: a rationally-designed regimen against colorectal carcinoma. Clin Res 36: abstract 803Google Scholar
  38. 38.
    Stolfi, RL, Martin DS, Sawyer RC, Spiegelman D (1983) Modulation of 5-fluorouracil- induced toxicity in mice with interferon or the interferon inducer, polynosinic-polycytidylic acid. Cancer Res 43: 561–566PubMedGoogle Scholar
  39. 39.
    Wadler S, Lyver A, Goldman M, Wiernik PH: Therapy with 5-fluorouracil (5FU) and recombinant alpha-2a interferon (IFN) in refractory GI-malignancies. Proc Am Soc Clin One 89, abstract 384Google Scholar
  40. 40.
    Clark PI, Slevin ML, Reznek RH, et al (1987) Two randomized Phase II trials with intermittent intravenous versus subcutaneous alpha-2-interferon alone and in combination with 5-fluoruracil in advanced colorectal carcinoma. Int J Color Dis 2: 26–29CrossRefGoogle Scholar
  41. 41.
    Chirigos MA, Pearson JW (1973) Brief communication: cure of murine leukemia with drug and interferon treatment. J Natl Can Inst (USA) 51: 1367–1368Google Scholar
  42. 42.
    Creagan ET, Kovach JS, Long HJ, Richardson RL (1986) Phase I study of recombinant leukocyte A human interferon combined with BCNU in selected patients with advanced cancer. J Clin Oncol 4: 408–413PubMedGoogle Scholar
  43. 43.
    Rosenblumm MG, Gutterman JV (1984) Synergestic antiproliferative activity of leukocyte interferon in combination with alpha difluormethylornithine against human cells in culture. Cancer Res 44: 2339–2340Google Scholar
  44. 44.
    Talpaz M, Plager C, Quesada J, et al (1986) Difluormethylornithine and leukocyte inter-feron: A phase I study in cancer patients. Eur J Clin Oncol 22: 685–689Google Scholar
  45. 45.
    Dritschilo A, Mossman K, Gray M, Sreevalsan T (1982) Potentation of radiation injury by interferon. Am J of Clin Oncol 5: 79–82Google Scholar
  46. 46.
    Gould MN, Kakria RC, Olson S, Borden EC (1984) Radiosensitisation of human bron-chogenic carcinoma cells by interferon beta. J Interferon Res 4: 123–128PubMedCrossRefGoogle Scholar
  47. 47.
    Nederman T, Benedikeson G (1982) Effects of interferon on growth rate and radiation sensitivity of cultured human glioma cells. ACTA Radiol Oncol 21: 231–234PubMedCrossRefGoogle Scholar
  48. 48.
    Chang AYC, Keng PC (1983) Inhibition of cell growth in synchronous human hypernephroma cells by recombinant interferon-aD and irridiation. J Interferon Res 3: 379–385PubMedCrossRefGoogle Scholar
  49. 49.
    Borden EC, Sidky YA: IFN-a/ß and irradiation: Protection against lethality and augmentation of antitumor effects. Proc Am Soc Clin One 89, abstract 1536Google Scholar
  50. 50.
    Horning SJ, Levine JF, Miller RA (1982) Clinical and immunological effects of recombinant leukocyte A interferon in eight patients with advanced cancer. JAMA 247: 1718–22PubMedCrossRefGoogle Scholar
  51. 51.
    Real FX, Krown SE, Nisce LZ, et al (1985) Unexpected toxicity from radiation therapy in two patients with Kaposi’s sarcoma receiving interferon. J Bio Resp Mod 4: 141–146Google Scholar
  52. 52.
    Torrisi J, Berg C, Harter K, et al (1985) Phase combined modality trial of alpha-2- interferon and radiotherapy. Proc Am Soc Clin One 4: 227 (abstr)Google Scholar
  53. 53.
    Holsti LR, Mattson K, Niiraen A, Standertskield-Nordenstam CG, Steuman S, Sovigavi A, Cantell K (1987) Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung. Int J Radiol Oncol Biol Phys 13 (8): 1161–6CrossRefGoogle Scholar
  54. 54.
    Fleischmann WR, Georgiades JA, Osborne LC, et al (1979) Potentation of interferon activity by mixed preparations of fibroblast and immune interferon. Infect Immun 26: 248–253PubMedGoogle Scholar
  55. 55.
    Zerial A, Hovanessian AG, Stefanos S (1982) Synergistic activities of type I (alpha, beta) and type II (gamma) murine interferons. Antiviral Res 2: 227–239PubMedCrossRefGoogle Scholar
  56. 56.
    Schwarz LA, Fleischmann CM, Fleischmann WR (1984) Potentiation of interferon’s antiviral activity by the mutually synergistic interaction of MU IFN alpha/beta and Mu IFN-gamma. J Biol Resp Mod 3: 608–612Google Scholar
  57. 57.
    Fleischmann WR (1982) Potentiation of direct anticellular activity of mouse interferon: Mutual synergism and interferon concentration dependence. Cancer Res 42: 869–8757PubMedGoogle Scholar
  58. 58.
    Fleischmann WR, Jr, Kleyn KM, Baron S (1980) Potentiation of antitumor effect of virus induced interferon by mouse immune interferon preparations. J Natl Cancer Inst 65: 963–966PubMedGoogle Scholar
  59. 59.
    Oleszak E, Stewart WE (1985) Potentiation of the antiviral and anticellular activities of interferons by mixtures of Hu IFN-gamma and Hu IFN-alpha or IFN-beta. J Inf Res 5: 361–371Google Scholar
  60. 60.
    Fleischmann WR, Jr, Fleischmann CM, Fiers W (1984) Potentiation of interferon action by mixtures of recombinant DNA derived human interferons. Antiviral Res 4: 357–360PubMedCrossRefGoogle Scholar
  61. 61.
    Denz H, Lechleitner M, Marth C, et al (1985) Effect of human recombinant alpha-2- and gamma-interferon on the growth of human cell lines from solid tumors and hematologic malignancies. J Interferon Res 5: 147–157PubMedCrossRefGoogle Scholar
  62. 62.
    Weigent DA, Langford MP, Fleischmann WR, Jr, et al (1983) Potentiation of natural killing by mixtures of alpha or beta interferon with recombinant gamma interferon. Infect and Immun 40: 35–38Google Scholar
  63. 63.
    Chang RJ, Assisi F, Lee SH (1984) The synergistic stimulation of the expression of Fc- receptors for immunoglobulin-G on a monocyte like cell line by gamma interferon and a human lymphotoxin. Lymphokine Res 3: 83Google Scholar
  64. 64.
    Chang AYC, Keng PC (1985) Effects of gamma interferon and radiation on synchronized human hypernephroma cells. Proc Am Assoc Cancer Res 26: 281Google Scholar
  65. 65.
    Kurzrock R, Rosenblum MG, Quesada JR, et al (1986) Phase I study of a combination of recombinant interferon gamma in cancer patients. J Clin One 4: 1677–1683Google Scholar
  66. 66.
    Foon KA, Doroshow J, Bonnern EM, et al: A prospective randomized trial of alpha 2b interferon/gamma interferon or the combination in advanced metastatic renal cell carcinoma. J Biol Response Mod 1988 Dec; 7 (6): 540–545PubMedGoogle Scholar
  67. 67.
    Osanto S, Van Dissel JT, Leigh PJ, et al: Combination treatment with human interferon alpha and gamma in metastatic melanoma. Fifth NIC-EORTC Symposium, October 2–24, 1986, Amsterdam (abstr 6–10)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • E. Bonnem
  • P. von Wussow

There are no affiliations available

Personalised recommendations